Form 4: Royalty Pharma CFO Sells Shares Under 10b5-1 Plan

Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 34,791 Class A Ordinary Shares for approximately $1.6 million through a pre-arranged 10b5-1 trading plan.

Summary

• Terrance P. Coyne, Executive Vice President and Chief Financial Officer of Royalty Pharma plc, reported the sale of 34,791 Class A Ordinary Shares.
• The sales occurred on March 2, 2026, at weighted average prices ranging from $46.6717 to $47.0145 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Mr. Coyne on August 8, 2025.
• Following these transactions, Mr. Coyne and controlled entities beneficially own 350,420 Class A Ordinary Shares directly and indirectly.
• Additionally, Mr. Coyne and family vehicles hold limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,807,277 Class A Ordinary Shares, subject to vesting conditions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's an insider sale, the 10b5-1 plan mitigates negative sentiment, and the executive retains significant holdings, indicating continued confidence.

Positives

• The sales were conducted under a pre-arranged 10b5-1 plan, indicating a structured, non-discretionary transaction rather than a reaction to new, negative information.
• Despite the sales, the reporting person retains substantial beneficial ownership, including significant exchangeable interests, demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even under a 10b5-1 plan, represents a reduction in direct equity exposure by a key executive.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• No direct management comments or notable quotes are included in this Form 4 filing, beyond the factual reporting of transactions.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan are common for executives to manage personal finances and diversify holdings without raising concerns about trading on material non-public information. This practice is standard across various industries for high-level executives.

Comparison to Industry Standards

• StockSavvy.ai observes that the sale of approximately $1.6 million in shares by a CFO, while notable, is not uncommon for executives at large-cap pharmaceutical royalty companies like Royalty Pharma.
• Compared to similar transactions by executives at companies such as Johnson & Johnson or Pfizer, where insider sales can often reach tens of millions, this transaction falls within a typical range for routine portfolio management, especially given the executive's substantial remaining holdings and exchangeable interests.

Related Party Transactions

• The reported transactions involve the sale of shares by Terrance P. Coyne, EVP & CFO, who is considered a related party to Royalty Pharma plc.

Stakeholder Impact

• Shareholders: The sale by a key executive could be perceived negatively, but the 10b5-1 plan context and substantial remaining holdings mitigate concerns about management's confidence in the company's future.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The insider sale, while a reduction in direct equity, was pre-planned under a 10b5-1 plan, which typically signals a routine financial management decision rather than a reaction to new company-specific information. The executive retains substantial beneficial ownership, including significant exchangeable interests, suggesting continued alignment with the company's long-term prospects. Therefore, this filing alone does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

Royalty Pharma, RPRX, Form 4, Insider Trading, Terrance P. Coyne, CFO, Share Sale, 10b5-1 Plan, Beneficial Ownership, Equity Sales